Tag Archives: Elizabeth Donley

NeuroPointDX

NeuroPointDX Validates Autism Test

NeuroPointDX, the diagnostics division of Stemina Biomarker Discover, has validated a first-generation autism diagnostic blood test panel in its Children’s Autism Metabolome Project (CAMP) clinical study, the organization announced recently….

Stemina

Stemina Prepares for Commercialization

Stemina Biomarker Discovery is preparing to go to market in early 2018 with its autism diagnostic test panel, the company announced recently. According to a release, Heiner Dreismann, the former head…

NeuroPointDX

NeuroPointDX, Ovid Therapeutics Collaborate

NeuroPointDX, the diagnostics division of Stemina Biomarker Discovery, and New York-based Ovid Therapeutics announced today they will team up to identify novel biomarkers of a rare genetic disorder called Angelman syndrome….

Stemina

Stemina Rebrands Its Diagnostics

Stemina Biomarker Discovery Inc., is rebranding its diagnostics to more accurately represent its focus on neurological disorders, the company announced recently. According to a release, NeuroPointDX, a division of Stemina,…

Stemina

Stemina Receives $2.7M Grant

Stemina Biomarker Discovery Inc., a company focused on diagnosis and individualized treatment of neurological disorders, received a $2.7 million grant from the National Institute of Mental Health (NIMH) to support the Children’s Autism…

Stemina

Stemina Lands $2.3M for Autism Study

The Nancy Lurie Marks Family Foundation is investing $2.3 million to support Stemina Biomarker Discovery‘s clinical study of biomarkers in the blood of children with autism spectrum disorders (ASD), the foundation…

Stemina

Stemina Earns $10M EPA Contract

Stemina Biomarker Discovery announced this week it received a five-year contract worth $10,637,000 from the U.S. Environmental Protection Agency (EPA) in conjunction with the federal agency’s ToxCast initiative. According to…